Please login to the form below

Not currently logged in
Email:
Password:

NICE rejects aggressive breast cancer drug

NICE has rejected GSK's Tyverb in combination with capecitabine for the treatment of an aggressive form of advanced breast cancer

The UK's National Institute for Health and Clinical Excellence (NICE) has issued its Appraisal Consultation Document (ACD) rejecting GlaxoSmithKline's (GSK) oral Tyverb (lapatinib) in combination with capecitabine for the treatment of an aggressive form of advanced breast cancer (ErbB2-positive).

The decision follows the July 2009 request of NICE's appeal panel that the appraisal committee should reconsider lapatinib under the Institute's end of life (EOL) supplementary guidance.

The EOL guidance was specifically developed to help small numbers of patients, who have only a few months to live, gain access to important new medicines. GSK submitted additional data demonstrating that lapatinib met all three of the EOL criteria. 

Though NICE recognised this, it felt lapatinib was still not a cost-effective use of NHS resources. This decision was made despite GSK offering the Tyverb Patient Access Programme, which allows National Health Service (NHS) patients in the UK free access to lapatinib for the first three months of treatment.   

Simon Jose, general manager, GSK UK, commented: "NICE developed additional criteria specifically to help secure greater patient access to new treatments that offer precious extra time at the end of life. It is disappointing that, despite acknowledging Tyverb meets these criteria and GSK offering to bear the cost of lapatinib for up to 12 weeks, NICE is still proposing to reject lapatinib. We will continue to offer our patient access programme to individual NHS Trusts to ensure patients have access to Tyverb."

Twenty-six Trusts have enrolled in the patient access programme to date. 

21st October 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics